علاج الالتهاب الرئوي بالمكورة العنقودية الذهبية في البالغين المستشفيين بالتهاب رئوي مكتسب من المجتمع الشديد

References

DOI: 10.1164/rccm.201908-1581ST

• In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):
• a b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or
• a b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).
• In switching from parenteral to oral antibiotics, either the same agent or the same drug class should be used.
• We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
• As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.